MAXIND.NSE News

In this briefing: Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (15 Dec) 2026 High Conviction: Tenneco Clean Air The Thermal Vs Renewable Debate: JSW Energy - 2026 High Conviction Idea APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem 1. Relative Value Opportunities in Asia-Pac, Pair Trade Roundup (15 Dec) Context: This Insight follows up on previously highlighted relative value opportunities, using a statistical methodology based on mean-reversion to identify opportunities in paired securities. Opportunity: Currently eight pair trade opportunities across four markets and five sectors persist. Why read: Statistical analysis offers a unique perspective on relative value. Gain insights into actionable statistical pair trade opportunities and monitor performance of previously highlighted pairs. 2. 2026 High Conviction: Tenneco Clean Air Tenneco Clean Air India Ltd (1880671D IN) is part of the Tenneco Group, a U.S.-headquartered global Tier I automotive component supplier.

In this briefing: 2026 High Conviction: Tenneco Clean Air The Thermal Vs Renewable Debate: JSW Energy - 2026 High Conviction Idea APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem JK Lakshmi Cement: Volume Momentum Remains Strong. Maintain BUY 1. 2026 High Conviction: Tenneco Clean Air Tenneco Clean Air India Ltd (1880671D IN) is part of the Tenneco Group, a U.S.-headquartered global Tier I automotive component supplier. It designs and manufactures clean air, powertrain, and suspension solutions for Indian OEMs and export markets. Since its listing, the stock is up 19%, but there is still upside potential. 2. The Thermal Vs Renewable Debate: JSW Energy - 2026 High Conviction Idea JSW has shown strong growth in generation capacity, with plans to double it to 30GW by 2030. The company is also venturing into ancillaries like battery assembly and hydrogen production.

In this briefing: Medical Data Vision (3902 JP): Nippon Life’s Rumoured Tender Offer at 3x the Last Close [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem Primer: Artrya (AYA AU) - Dec 2025 RadNet: Focusing On The Future of Imaging With AI Adoption and Strategic Partnerships; Will It Pan Out? 1. Medical Data Vision (3902 JP): Nippon Life’s Rumoured Tender Offer at 3x the Last Close The Nikkei reports that Nippon Life Insurance will launch a tender offer for Medical Data Vision (3902 JP) at a valuation up to JPY60 billion. If the valuation refers to market cap, the offer is JPY1,500, a 225% premium to the last close of JPY462. If it relates to EV, the offer price is JPY1,550. Despite the staggering premium, it does not represent an all-time high (share price traded higher in November 2021). Nevertheless, a binding proposal would be a done deal. 2. [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Medical Data Vision (3902 JP) was IPOed in 2014.

In this briefing: Primer: Shikoku Electric Power Co (9507 JP) - Dec 2025 Primer: Gumi Inc (3903 JP) - Dec 2025 Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation Wealthfront Corporation (WLTH): Financial Platform Falls Flat Despite Heavy Pre-IPO Interest Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem 1. Primer: Shikoku Electric Power Co (9507 JP) - Dec 2025 Shikoku Electric Power is demonstrating a significant financial turnaround, with net income rebounding strongly in the latest fiscal years after a loss in FY2023, driven by operational efficiencies and a favorable regulatory environment. The company is strategically expanding its renewable energy portfolio, with a target to increase capacity to 500MW by FY2030 and 2GW by FY2050, focusing on solar (including floating solar), biomass, and wind power. The stable operation of its sole nuclear reactor, Ikata Unit 3, is a critical earnings driver, though it remains subject to regulatory oversight, legal challenges, and periodic maintenance shutdowns.

In this briefing: [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem Primer: Artrya (AYA AU) - Dec 2025 RadNet: Focusing On The Future of Imaging With AI Adoption and Strategic Partnerships; Will It Pan Out? Roivant Sciences: From Batoclimab Breakthroughs to Global Trials—A Rising Contender in Autoimmune Therapeutics! 1. [Japan M&A?] Nikkei Reports Nippon Life to Buy Medical Data Vision (3902) For ~¥60bn Medical Data Vision (3902 JP) was IPOed in 2014. MitCorp sold. Others sold. Fujifilm and Medipal stayed in. The stock ran up. SBI bought from Fujifilm in Nov2020 at ¥2355. The stock fell, SBI bought more in 2021-2022. Then it fell more in 2023 and SBI bought more, then fell more in 2024 and SBI bought more. The Nikkei reports today that Nippon Life will announce a TOB on 15 December with a max price of ¥60bn (242% premium), which coincidentally would bring SBI close to breakeven. 2.

In this briefing: Primer: Gumi Inc (3903 JP) - Dec 2025 Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation Wealthfront Corporation (WLTH): Financial Platform Falls Flat Despite Heavy Pre-IPO Interest Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem Primer: The Walt Disney Co (DIS US) - Dec 2025 1. Primer: Gumi Inc (3903 JP) - Dec 2025 Strategic Pivot to Web3 and Metaverse: Gumi is aggressively shifting its focus from a reliance on hit-driven mobile games to becoming a comprehensive Web3 enterprise, underscored by strategic partnerships with Square Enix and SBI Holdings, and significant investments in cryptocurrencies like XRP and Bitcoin. Financial Volatility and Restructuring: The company has experienced significant financial turbulence, with a substantial net loss in FY24 driven by underperforming titles, leading to the discontinuation of flagship games, workforce reductions, and a halt in the development of high-risk original titles.

In this briefing: Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation Wealthfront Corporation (WLTH): Financial Platform Falls Flat Despite Heavy Pre-IPO Interest Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem Primer: The Walt Disney Co (DIS US) - Dec 2025 2026 IPOs Pipeline (USA and Europe) 1. Rohm (6963 JP): Renewed Growth, Conservative Guidance & Reasonable Valuation Sales are growing again and the company has turned profitable with capacity utilization up and costs down. Guidance for 2H of FY Mar-26 looks conservative. Sales of power devices is rising after a long period of weakness, supported by auto, industrial and data center related demand. Projected valuations are once again reasonable. The share price should continue to trend upwards. 2. Wealthfront Corporation (WLTH): Financial Platform Falls Flat Despite Heavy Pre-IPO Interest Wealthfront priced 34.6mm shares at $14.00, top of range, and opened flat before closing up 1.4% after a volatile first session.

In this briefing: APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem JK Lakshmi Cement: Volume Momentum Remains Strong. Maintain BUY Company Update: Tata Steel Ltd - 12 Th December, 2025 Thematic Report On India’s Valuation Reset: How Markets Are Repricing Growth Heading Into 2026 1. APAC Healthcare Weekly (December 14) – China NRDL, Fosun Pharma, SanBio, Peptidream, Zydus Life China has published 2025 National Reimbursement Drug List, which will be officially implemented nationwide on January 1, 2026. The list added 114 new drugs, including 50 Class 1 innovative drugs. Fosun Pharmaceutical subsidiary inked exclusive global collaboration and license agreement with Pfizer for weight loss drug candidate YP05002. SanBio obtained partial change approval to the marketing authorization for Akuugo. PeptiDream achieved milestone of nominating a clinical development candidate from collaboration program with Asahi Kasei.

In this briefing: Amdocs: Looking To Reinvent Telecom Software With Agentic AI—Here’s Why It Matters! Shift4 Payments: Can This Powerful Global Blue Expansion Unlock a New Wave of Growth? Pinterest + tvScientific = Ad Game Changer? The Synergies You Need to Know! Taiwan Dual-Listings Monitor: TSMC Historically High Premium Cracks; ChipMOS & CHT Opportunities Max India: The Next Megatrend Play – Scaling India's Only Integrated Senior Care Ecosystem 1. Amdocs: Looking To Reinvent Telecom Software With Agentic AI—Here’s Why It Matters! Amdocs reported its financial performance for the fourth quarter and full fiscal year of 2025, signaling key trends within the company and its strategic direction. On a pro forma constant currency basis—accounting for the phaseout of certain low-margin noncore business activities—Amdocs achieved revenue growth of 3.1% for the fiscal year. In the fourth quarter, revenue reached $1.15 billion, showing a 2.8% increase compared to the previous year in pro forma constant currency terms. 2.